.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The POISE-2 randomized trial evaluated whether perioperative aspirin could reduce major cardiovascular events in patients undergoing noncardiac surgery who were at risk for vascular complications. Routine aspirin did not reduce the composite risk of death or nonfatal myocardial infarction, but it did increase clinically important bleeding. The result is highly relevant to perioperative decision-making because antiplatelet therapy can be intuitively attractive when cardiovascular risk is high, yet surgery changes the balance between thrombosis and bleeding. For surgeons, anesthetists and physicians, the practical lesson is not to start aspirin simply because a patient is undergoing major surgery. Instead, the decision should consider the indication for antiplatelet therapy, previous coronary intervention, cardiovascular risk, procedure-specific bleeding risk and the overall perioperative plan. The study also illustrates why large pragmatic trials are valuable: a common intervention that seems biologically plausible may not improve outcomes when used broadly. Individualized medication management remains essential, particularly in patients already receiving antiplatelet therapy for established cardiovascular disease.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The POISE-2 randomized trial evaluated whether perioperative aspirin could reduce major cardiovascular events in patients undergoing noncardiac surgery who were at risk for vascular complications. Routine aspirin did not reduce the composite risk of death or nonfatal myocardial infarction, but it did increase clinically important bleeding. The result is highly relevant to perioperative decision-making because antiplatelet therapy can be intuitively attractive when cardiovascular risk is high, yet surgery changes the balance between thrombosis and bleeding. For surgeons, anesthetists and physicians, the practical lesson is not to start aspirin simply because a patient is undergoing major surgery. Instead, the decision should consider the indication for antiplatelet therapy, previous coronary intervention, cardiovascular risk, procedure-specific bleeding risk and the overall perioperative plan. The study also illustrates why large pragmatic trials are valuable: a common intervention that seems biologically plausible may not improve outcomes when used broadly. Individualized medication management remains essential, particularly in patients already receiving antiplatelet therapy for established cardiovascular disease.
4 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
